James Hu

Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial

Hussein A. Tawbi, Melissa Burgess, Vanessa Bolejack et al. · The Lancet Oncology · 2017 · 1.4K citations · Full text

Oncology, Pathology, Advanced Soft-tissue Sarcoma +5

Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab

Emily Z. Keung, Melissa Burgess, Ruth Salazar et al. · Clinical Cancer Research · 2020 · 191 citations · Full text

Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS): Final results of SARC028 expansion cohorts.

Melissa Burgess, Vanessa Bolejack, Scott M. Schuetze et al. · Journal of Clinical Oncology · 2019 · 129 citations

Primary Endpoint, Immunology, Pathology +18

Atezolizumab for Advanced Alveolar Soft Part Sarcoma

Alice P. Chen, Elad Sharon, Geraldine O’Sullivan Coyne et al. · New England Journal of Medicine · 2023 · 124 citations · Full text

Safety and efficacy of PD-1 blockade using pembrolizumab in patients with advanced soft tissue (STS) and bone sarcomas (BS): Results of SARC028—A multicenter phase II study.

Hussein Tawbi, Melissa Burgess, John Crowley et al. · Journal of Clinical Oncology · 2016 · 60 citations

Pd-1 Blockade, Immunology, Immunoediting +16